戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 as partially reversible by depleting UA with rasburicase.
2 sly days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d days 1 to 3 followed by oral al
3 sis syndrome (TLS) were randomly assigned to rasburicase (0.20 mg/kg/d intravenously days 1-5), rasbu
4 ol in hyperuricemic patients was 4 hours for rasburicase, 4 hours for rasburicase plus allopurinol, a
5  Plasma uric acid response rate was 87% with rasburicase, 78% with rasburicase plus allopurinol, and
6                 Ninety-two patients received rasburicase, 92 rasburicase plus allopurinol, and 91 all
7 evaluated safety of and compared efficacy of rasburicase alone with rasburicase followed by oral allo
8 k of a patient of having TLS and can include rasburicase and allopurinol.
9 syndrome necessitates intravenous hydration, rasburicase, and management of associated electrolyte ab
10 after the first dose, patients randomized to rasburicase compared to allopurinol achieved an 86% vers
11 ts at high risk for tumor lysis who received rasburicase compared to allopurinol.
12  compared efficacy of rasburicase alone with rasburicase followed by oral allopurinol and with allopu
13  AUC(0-96) was 128 +/- 70 mg/dL.hour for the rasburicase group and 329 +/- 129 mg/dL.hour for the all
14 ter randomized trial compared allopurinol to rasburicase in pediatric patients with leukemia or lymph
15                                              Rasburicase is a new recombinant form of urate oxidase a
16 tage lymphoma or high tumor burden leukemia, rasburicase is a safe and effective alternative to allop
17                                              Rasburicase is effective in controlling plasma uric acid
18                                              Rasburicase is safe and highly effective for the prophyl
19                   Recombinant urate oxidase (rasburicase) is a newer agent that directly cleaves uric
20  end, the experimental setup was tested with rasburicase (known to be very sensitive to denaturation)
21  a number of drugs (for example, primaquine, rasburicase), or, more rarely, by infection.
22 icase (0.20 mg/kg/d intravenously days 1-5), rasburicase plus allopurinol (rasburicase 0.20 mg/kg/d d
23 nts was 4 hours for rasburicase, 4 hours for rasburicase plus allopurinol, and 27 hours for allopurin
24 onse rate was 87% with rasburicase, 78% with rasburicase plus allopurinol, and 66% with allopurinol.
25 Ninety-two patients received rasburicase, 92 rasburicase plus allopurinol, and 91 allopurinol.
26  with hyperuricemia or at high risk for TLS, rasburicase provided control of plasma uric acid more ra
27 useful to optimize the use of allopurinol or rasburicase remains to be determined.
28             It was significantly greater for rasburicase than for allopurinol (P = .001) in the overa
29                      The pharmacokinetics of Rasburicase, the urinary excretion rate of allantoin, an
30 excretion rate of allantoin increased during Rasburicase treatment, peaking on day 3.
31                                          The rasburicase versus allopurinol group experienced a 2.6-f
32                                              Rasburicase was well tolerated as a single agent and in
33 cretion rate of allantoin, and antibodies to Rasburicase were also studied.